Baird lowered the firm’s price target on Enanta (ENTA) to $20 from $26 and keeps an Outperform rating on the shares. The firm said the Q4 report was straightforward, and noted they are on the precipice of the crucial RSVPEDs readout in December, which Baird thinks will be the key determinant of zelicapavir’s future potential in RSV.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENTA:
- Enanta price target lowered to $21 from $22 at JMP Securities
- Enanta Pharmaceuticals Reports Q4 2024 Financials
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Enanta reports Q4 EPS ($1.36), consensus (92c)
- Enanta Pharmaceuticals (ENTA) Q4 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
